Transgender Women & HIV Research Study
Researchers at Johns Hopkins University are conducting a study with transgender women diagnosed with HIV.
Fast Facts
Transgender Woman
Ages 18+
Diagnosed with HIV
Compensation Provided
Conducted in Baltimore, MD
Study Background
Johns Hopkins University is Giving Standardized Estradiol Therapy In Transgender Women to Research Interactions with HIV Therapy: the GET IT RIgHT Study.
Transgender women (TW) are the fastest-growing group of people with HIV. The purpose of this study is to determine the best combination of HIV treatment for transgender women living with HIV who take feminizing hormonal therapy (FHT).
All participants will receive FHT. The study will determine if TW remain undetectable while receiving FHT for 48 weeks. Additionally, it will assess if hormone levels change based on the type of HIV medication taken.
Participants enrolled in the study will complete a screening visit, and follow-up visits at weeks 4, 8, 12, 24, 36, and 48. All visits will be in person except week 8, which will be a phone call.
Findings from this study will determine whether transgender women continue to achieve therapeutic concentrations of ART while receiving FHT for 48 weeks.
Further research and join our compensated study.
Study Background
Johns Hopkins University is Giving Standardized Estradiol Therapy In Transgender Women to Research Interactions with HIV Therapy: the GET IT RIgHT Study.
Transgender women (TW) are the fastest-growing group of people with HIV. The purpose of this study is to determine the best combination of HIV treatment for transgender women living with HIV who take feminizing hormonal therapy (FHT).
All participants will receive FHT. The study will determine if TW remain undetectable while receiving FHT for 48 weeks. Additionally, it will assess if hormone levels change based on the type of HIV medication taken.
Participants enrolled in the study will complete a screening visit, and follow-up visits at weeks 4, 8, 12, 24, 36, and 48. All visits will be in person except week 8, which will be a phone call.
Findings from this study will determine whether transgender women continue to achieve therapeutic concentrations of ART while receiving FHT for 48 weeks.
Further research and join our compensated study.
Additional Information
The purpose of this research study is to determine the best combination of HIV treatment for transgender women living with HIV who take feminizing hormonal therapy.
You may qualify for this study if you meet the following criteria.
Inclusion Criteria:
- Ages 18+
- Diagnosed with HIV
- Identify as a Transgender Woman, Female, Transfeminine person, or Nonbinary/Genderfluid
- Male sex assigned at birth
- Motivated to start feminizing hormone therapy (estrogen), or willing to stop it for at least 14 days and then restart it
- On HIV treatment for at least 24 weeks
- No history of breast cancer or testicular cancer
Once enrolled, this study involves:
- Completing a screening visit followed by enrollment into the study within 60 days
- Receiving feminizing hormonal therapy (FHT) for 48 weeks
- Attending follow-up visits at weeks 4, 8, 12, 24, 36, and 48
- All visits will be in person except week 8, which will be a phone call.
Compensation is provided.
There is no cost for you to participate in our research study.
